Revolutionary Cancer Study: Nivolumab Yields Remarkable Results for Endometrial Cancer Patients
Nivolumab, an immunotherapy drug, shows an 80% complete response rate in phase 2 trials for resectable dMMR/MSI-H endometrial cancer. The trial results, announced at the 2025 SGO Annual Meeting, suggest reduced need for surgery among patients with total tumour remission. One patient
